• br Perspectives br Acknowledgments This

  2024-01-17

  

  Perspectives Acknowledgments This investigation was supported by a Research Grant 2010/01385-5 from FAPESP (Sao Paulo Research Foundation, Brazil). P.F.S. was recipient of a CNPq (National Council for Scientific and Technological Development, Brazil) productivity grant. R.F.A. was recipient of

• N terminally extended antigenic peptide precursors

  2024-01-17

  

  N-terminally extended antigenic peptide precursors that survive cytosolic degradation and enter the ER, need to be further processed by ERAP1 and/or ERAP2, in order to acquire the right length required for MHCI binding. ERAP1 (ERAAP in mouse) is an IFN-γ-inducible, metalloaminopeptidase that trims N

• br Conclusion br Introduction Lung cancer is the principal c

  2024-01-17

  

  Conclusion Introduction Lung cancer is the principal cause of death by cancer and the third most common cancer worldwide (Sorber et al., 2016). Lung cancer has two main types: small cell carcinomas (approximately 20%) and non-small cell lung cancers (NSCLC) (about 80%) (Fan et al., 2016). NSC

• While HTPCs are not immune cells they produce IL

  2024-01-17

  

  While HTPCs are not immune cells, they produce IL-6, MCP-1 and other immunologically relevant factors (Mayer et al., 2016). Our results demonstrated that epinephrine and phenylephrine increased the mRNA expression levels of COX-2, IL-6 and MCP-1 in HTPCs without affecting the mRNA expression level o

• ACK has been clearly implicated

  2024-01-16

  

  ACK1 has been clearly implicated in cancer progression in recent years. A strong correlation between ACK1 gene copy number, protein level and activity have been demonstrated in tumors of different tissue types (Mahajan et al., 2007; van der Horst et al., 2005; Wang et al., 2006). Our western blot an

• br Difference between ACh and ER tests There are

  2024-01-16

  

  Difference between ACh and ER tests There are few reports concerning the provoked spasm between ER and ACh in the same patients [51], [52], [53]. Different mediators may have the potential of different coronary responses. In our experience, spasm provoked by intracoronary injection of ER is focal

• The small fishers with little or no quota

  2024-01-16

  

  The small fishers with little or no quota who remained relied on quota leasing arrangements to continue their fishing operations. Such arrangements had relatively high transaction costs and by early 2000 it appeared that the demise of the small fisher was imminent [2]. The introduction in 2001 of t

• Western blot results showed that the expressions of SOCS and

  2024-01-16

  

  Western blot results showed that the expressions of SOCS1 and SOCS3 significantly increased after administration of rGas6 24h after MCAO (Fig. 7A–C p Discussion After ischemic stroke, inflammation has been shown to be an important secondary injury mediator in patients, as well as in animals (Herz

• Zhang et al screened three thousand compounds

  2024-01-16

  

  Zhang et al. screened three thousand compounds library and found two active 3,5,6-substituted indolin-2-one molecules. Further, they designed various derivatives of this scaffold and among them compound 23 from the series was found active with 1.8 μM on Aurora-B kinase luminescent assay [53]. Jeffe

• Earlier studies showed that exposure of

  2024-01-16

  

  Earlier studies showed that exposure of cells to IR caused ATM-dependent phosphorylation of 53BP1, as judged by electrophoretic mobility shift [24], [25], [26]. To date, the only known in vivo 53BP1 phosphorylation site(s) are Ser25 and possibly Ser29 [27]. In the course of our studies, we noticed t

• br Experimental br Results and discussion br Conclusion br

  2024-01-16

  

  Experimental Results and discussion Conclusion Acknowledgments This work is supported by the National Basic Research Program of China (973 Program 2016YFA0201201 and 2013CB932702), a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAP

• br Acknowledgments and Disclosures br

  2024-01-16

  

  Acknowledgments and Disclosures Introduction Over the last decade, the most visible strategy for the treatment of Alzheimer's disease (AD) has been amyloid β peptide (Aβ) immunotherapy (reviewed in [1]). Although the first efforts with Aβ immunotherapy failed to complete clinical trials [1], A

• Secondly as pointed out by Sulentic and Kaminski

  2024-01-15

  

  Secondly, as pointed out by Sulentic and Kaminski in their recent paper [90], most of the AhR literature to date has focused on mouse AhR. Although both mouse and human AhR are interchangeable in many in vitro systems, the in vivo ligand binding affinity is drastically different between the two AhRs

• Patients with AAG often respond

  2024-01-15

  

  Patients with AAG often respond to intravenous immunoglobulin or plasma exchange. If these therapies are inadequate, ongoing immune suppression with steroids, azathioprine, mycophenylate or rituximab have been shown to be effective in case reports. Our patient seemed initially resistant to steroid t

• It has been recognized for

  2024-01-15

  

  It has been recognized for decades that neurons in the mammalian central nervous system may release both a fast-acting, typically amino acid derived neurotransmitter such as glutamate or GABA, and a second peptidergic neuromodulatory molecule such as neuropeptide Y, substance P, or cholecystokinin.

14809 records 163/988 page Previous Next First page 上5页 161162163164165 下5页 Last page